Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More
Summary
GSK president and chief scientific officer Hal Barron called PARP blockers “under-appreciated” when the firm bought Tesaro and its drug niraparib (Zejula) last December. —The European Society of Medical Oncology’s annual meeting featured notable updates for PARP inhibitors, potential advances in breast and prostate cancer treatment, and much more. —BioCentury scooped that President Trump would soon nominate Stephen Hahn, chief medical executive of Houston’s MD Anderson Cancer Center, as the next FDA commissioner. —The heat was turned up more this week on Sarepta Therapeutics (NASDAQ: SRPT), whose shares have been sliding since an FDA rejection of its Duchenne muscular dystrophy drug golodirsen. —Shares of Minerva Neurosciences (NASDAQ: NERV) fell 28 percent after the company disclosed that a “cyberattack” at one of its contractors delayed enrollment in a Phase 3 trial of its schizophrenia drug roluperidone.
Classifications
AskAI Classifications
LabelsLinked Companies
